ReviewViruses2023
The Re-Emergence of Hepatitis E Virus in Europe and Vaccine Development.
Review in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hepatitis E Virus (HEV) Infection in the Context of the One Health Approach: A Systematic Review.Pathogens (Basel, Switzerland) · 2025Pooled it
- Hospital Admissions for Hepatitis A and E in Spain: Nationwide Trends and In-Hospital Outcomes.Journal of medical virology · 2026Article
- Extra-Hepatic Manifestations of Hepatitis E Virus (HEV): A Narrative Review on Meningoencephalitis.Life (Basel, Switzerland) · 2026Review
- Hepatitis E in Thailand: From Seroprevalence to Foodborne and Transfusion-Associated Risks.Journal of clinical medicine · 2026Review
- Paired In-Hospital Dynamics in Hepatitis E: Rapid Transaminase Decline and Persistent Hyperbilirubinemia in a Romanian Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Multiplex serological screening of wild boar as sentinels of emerging zoonoses: HEV, WNV, and TBEV distribution in Saxony, Germany.One health (Amsterdam, Netherlands) · 2025Article
- Bioinformatics Analysis of the Key lncRNAs of the Viral Response Pathway in HepG2 Expressing Genotype IV Swine Hepatitis E Virus ORF3.Microorganisms · 2025Article
- Design and Analysis of Novel HEV Vaccine Variants and Evaluation of Two Selected Candidates in a Porcine Infection Model.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Distribution ofParasite epidemiology and control · 2025Review
- How Can Plant-Derived Natural Products and Plant Biotechnology Help Against Emerging Viruses?International journal of molecular sciences · 2025Review
- HEV-3 subtypes and strains detected in cases of HEV infection in central Italy from 2015 to 2023.Infection · 2025Article
- Hepatitis E virus (HEV) infection among the Arab population in Northern Israel: an insight into the seroepidemiology and associated risk factors.Epidemiology and infection · 2025Article
- Detection of Rocahepevirus ratti in Bivalve Mollusks from São Luís Island, Maranhão, Brazil: A Potential Transmission Route of an Emerging Zoonotic Pathogen?Food and environmental virology · 2025Article
- Evidence of hepatitis E virus in milk and feces from rural cattle farms in Mazandaran province, Iran.Veterinary research forum : an international quarterly journal · 2025Article
- Hepatitis E and Potential Public Health Implications from a One-Health Perspective: Special Focus on the European Wild Boar (Pathogens (Basel, Switzerland) · 2024Review
- From discovery to treatment: tracing the path of hepatitis E virus.Virology journal · 2024Review
- Current perspectives of viral hepatitis.World journal of gastroenterology · 2024Review
- Hepatitis E Virus in Domestic Ruminants and Virus Excretion in Milk-A Potential Source of Zoonotic HEV Infection.Viruses · 2024Review
- Detection of Hepatitis E Virus (HEV) in Pork Sold in Saint-Louis, the North of Senegal.Life (Basel, Switzerland) · 2024Article
- Hepatitis E Virus (HEV) Infection Among Immunocompromised Individuals: A Brief Narrative Review.Infection and drug resistance · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis E virus (HEV) is one of the leading causes of acute viral hepatitis. Transmission of HEV mainly occurs via the fecal-oral route (ingesting contaminated water or food) or by contact with infected animals and their raw meat products. Some animals, such as pigs, wild boars, sheep, goats, rabbits, camels, rats, etc., are natural reservoirs of HEV, which places people in close contact with them at increased risk of HEV disease. Although hepatitis E is a self-limiting infection, it could also lead to severe illness, particularly among pregnant women, or chronic infection in immunocompromised people. A growing number of studies point out that HEV can be classified as a re-emerging virus in developed countries. Preventative efforts are needed to reduce the incidence of acute and chronic hepatitis E in non-endemic and endemic countries. There is a recombinant HEV vaccine, but it is approved for use and commercially available only in China and Pakistan. However, further studies are needed to demonstrate the necessity of applying a preventive vaccine and to create conditions for reducing the spread of HEV. This review emphasizes the hepatitis E virus and its importance for public health in Europe, the methods of virus transmission and treatment, and summarizes the latest studies on HEV vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.